WeVote
Log In

Bill

DB

Bill

A 4015

Requires pharmacies to provide certain information regarding insulin manufacturer assistance programs.

2024-2025 Regular Session Introduced by Dave Bailey and 4 co-sponsors

New Jersey pharmacies must inform insulin patients about manufacturer assistance programs to reduce medication costs and improve treatment access.

Substituted by S2886 (1R)
#pharmaceutic
0
WeVote Research Nonpartisan
Bill Summary · A 4015

Legislative bill overview

Assembly Bill A 4015 requires New Jersey pharmacies to provide patients with information about insulin manufacturer assistance programs that can help reduce out-of-pocket costs. The bill was introduced in 2024 and has progressed through committee with amendments, though it was recently substituted by Senate Bill S2886, indicating the legislative approach may have shifted.

Why is this important

Insulin is a life-sustaining medication with costs that have risen dramatically, making it unaffordable for many patients despite insurance coverage due to high deductibles and copays. Requiring pharmacies to actively inform patients about manufacturer assistance programs could connect vulnerable populations to financial relief they may not know exists, potentially preventing dangerous medication rationing or non-compliance.

Potential points of contention

  • Implementation burden: Pharmacies may argue the requirement creates additional administrative costs and time demands during already-busy operations without state funding to offset compliance
  • Assistance program eligibility: Manufacturer programs have varying income limits and coverage criteria that may not help all patients, raising questions about whether the bill oversells the solution
  • Liability and liability concerns: Unclear responsibility if patients are misinformed, denied assistance, or if pharmacies fail to provide information consistently across locations

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.